Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study

Yoon Suk Jung, Minkyung Han, Won Ho Kim, Sohee Park, Jae Hee Cheon

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The incidence of inflammatory bowel disease (IBD) is increasing in East Asia; however, population-based data from this region are lacking. Aim: We conducted a nationwide, population-based study to examine the incidence and disease course of IBD in South Korea. Methods: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD [10,049 with ulcerative colitis (UC) and 5595 with Crohn’s disease (CD)] from 2011 to 2014. Results: During the study period, the average annual incidence of UC was 5.0 per 105, while that of CD was 2.8 per 105. Among patients with UC, the cumulative rates of surgery 1 and 4 years after diagnosis were 1.0 and 2.0%; those among patients with CD were 9.0 and 13.9%, respectively. The 1- and 4-year cumulative rates of moderate- to high-dose corticosteroid use were, respectively, 26.6 and 45.2% among patients with UC, and 29.9 and 50.8% among those with CD. Similarly, the 1- and 4-year cumulative rates of immunomodulator use were 14.1 and 26.4% among patients with UC, and 58.3 and 76.1% among those with CD, respectively. With regard to biologic use, the 1- and 4-year cumulative rates were 3.0 and 9.0% among patients with UC, and 11.1 and 31.7% among those with CD, respectively. Conclusions: The recent incidence of IBD in South Korea has been the highest in East Asia. Patients who had been diagnosed recently with IBD showed lower rates of surgery and higher rates of immunomodulator and biologic use compared to those reported ever in South Korea.

Original languageEnglish
Pages (from-to)2102-2112
Number of pages11
JournalDigestive diseases and sciences
Volume62
Issue number8
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

Republic of Korea
Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn Disease
Incidence
Population
Far East
Immunologic Factors
National Health Programs
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

@article{04f0f360af0940ee977ca2f37a8c437e,
title = "Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study",
abstract = "Background: The incidence of inflammatory bowel disease (IBD) is increasing in East Asia; however, population-based data from this region are lacking. Aim: We conducted a nationwide, population-based study to examine the incidence and disease course of IBD in South Korea. Methods: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD [10,049 with ulcerative colitis (UC) and 5595 with Crohn’s disease (CD)] from 2011 to 2014. Results: During the study period, the average annual incidence of UC was 5.0 per 105, while that of CD was 2.8 per 105. Among patients with UC, the cumulative rates of surgery 1 and 4 years after diagnosis were 1.0 and 2.0{\%}; those among patients with CD were 9.0 and 13.9{\%}, respectively. The 1- and 4-year cumulative rates of moderate- to high-dose corticosteroid use were, respectively, 26.6 and 45.2{\%} among patients with UC, and 29.9 and 50.8{\%} among those with CD. Similarly, the 1- and 4-year cumulative rates of immunomodulator use were 14.1 and 26.4{\%} among patients with UC, and 58.3 and 76.1{\%} among those with CD, respectively. With regard to biologic use, the 1- and 4-year cumulative rates were 3.0 and 9.0{\%} among patients with UC, and 11.1 and 31.7{\%} among those with CD, respectively. Conclusions: The recent incidence of IBD in South Korea has been the highest in East Asia. Patients who had been diagnosed recently with IBD showed lower rates of surgery and higher rates of immunomodulator and biologic use compared to those reported ever in South Korea.",
author = "Jung, {Yoon Suk} and Minkyung Han and Kim, {Won Ho} and Sohee Park and Cheon, {Jae Hee}",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s10620-017-4640-9",
language = "English",
volume = "62",
pages = "2102--2112",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "8",

}

Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014 : A Nationwide Population-Based Study. / Jung, Yoon Suk; Han, Minkyung; Kim, Won Ho; Park, Sohee; Cheon, Jae Hee.

In: Digestive diseases and sciences, Vol. 62, No. 8, 01.08.2017, p. 2102-2112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014

T2 - A Nationwide Population-Based Study

AU - Jung, Yoon Suk

AU - Han, Minkyung

AU - Kim, Won Ho

AU - Park, Sohee

AU - Cheon, Jae Hee

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: The incidence of inflammatory bowel disease (IBD) is increasing in East Asia; however, population-based data from this region are lacking. Aim: We conducted a nationwide, population-based study to examine the incidence and disease course of IBD in South Korea. Methods: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD [10,049 with ulcerative colitis (UC) and 5595 with Crohn’s disease (CD)] from 2011 to 2014. Results: During the study period, the average annual incidence of UC was 5.0 per 105, while that of CD was 2.8 per 105. Among patients with UC, the cumulative rates of surgery 1 and 4 years after diagnosis were 1.0 and 2.0%; those among patients with CD were 9.0 and 13.9%, respectively. The 1- and 4-year cumulative rates of moderate- to high-dose corticosteroid use were, respectively, 26.6 and 45.2% among patients with UC, and 29.9 and 50.8% among those with CD. Similarly, the 1- and 4-year cumulative rates of immunomodulator use were 14.1 and 26.4% among patients with UC, and 58.3 and 76.1% among those with CD, respectively. With regard to biologic use, the 1- and 4-year cumulative rates were 3.0 and 9.0% among patients with UC, and 11.1 and 31.7% among those with CD, respectively. Conclusions: The recent incidence of IBD in South Korea has been the highest in East Asia. Patients who had been diagnosed recently with IBD showed lower rates of surgery and higher rates of immunomodulator and biologic use compared to those reported ever in South Korea.

AB - Background: The incidence of inflammatory bowel disease (IBD) is increasing in East Asia; however, population-based data from this region are lacking. Aim: We conducted a nationwide, population-based study to examine the incidence and disease course of IBD in South Korea. Methods: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD [10,049 with ulcerative colitis (UC) and 5595 with Crohn’s disease (CD)] from 2011 to 2014. Results: During the study period, the average annual incidence of UC was 5.0 per 105, while that of CD was 2.8 per 105. Among patients with UC, the cumulative rates of surgery 1 and 4 years after diagnosis were 1.0 and 2.0%; those among patients with CD were 9.0 and 13.9%, respectively. The 1- and 4-year cumulative rates of moderate- to high-dose corticosteroid use were, respectively, 26.6 and 45.2% among patients with UC, and 29.9 and 50.8% among those with CD. Similarly, the 1- and 4-year cumulative rates of immunomodulator use were 14.1 and 26.4% among patients with UC, and 58.3 and 76.1% among those with CD, respectively. With regard to biologic use, the 1- and 4-year cumulative rates were 3.0 and 9.0% among patients with UC, and 11.1 and 31.7% among those with CD, respectively. Conclusions: The recent incidence of IBD in South Korea has been the highest in East Asia. Patients who had been diagnosed recently with IBD showed lower rates of surgery and higher rates of immunomodulator and biologic use compared to those reported ever in South Korea.

UR - http://www.scopus.com/inward/record.url?scp=85020238328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020238328&partnerID=8YFLogxK

U2 - 10.1007/s10620-017-4640-9

DO - 10.1007/s10620-017-4640-9

M3 - Article

C2 - 28593437

AN - SCOPUS:85020238328

VL - 62

SP - 2102

EP - 2112

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 8

ER -